The effect of carboplatin on renal function in patients with metastatic germ cell tumours

Mason,; Nicholls, J.; Horwich, A.

doi:10.1038/bjc.1991.144

Cited by 13 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…carboplatin effected neither renal function nor kidney histology in either species. These findings concur with their relative clinical nephrotoxicity since cisplatin can cause severe and irreversible damage to renal function in man (Daugaard et al, 1988) while the toxicity of carboplatin is confined to the reductions in GFR after high-dose therapy (Gore et al, 1987) and the possibility of cumulative reductions in GFR in some patient groups (Sleijfer et al, 1989;Mason et al, 1990).…”

Section: Discussionsupporting

confidence: 70%

Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents

McKeage

Morgan²,

Boxall³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

The comparative nephrotoxicity of i.v. cisplatin, i.v. carboplatin and six p.o. ammine/amine Pt(IV) dicarboxylates was studied in rodents following single MTD treatments. In mice, i.v. cisplatin caused proteinuria (1 g l-1), glycosuria (16.7 mM) and decreased GFR at 4 days, and histological kidney damage with onset at 6 days. In contrast, mice treated with i.v. carboplatin or p.o. ammine/amine Pt(IV) dicarboxylates had urinary glucose, urinary protein, GFR and kidney histology within the control range. In rats, i.v. cisplatin caused 5-fold elevations in plasma creatinine (188 +/- 33 microM) and urea (30.4 +/- 8.9 mM), a 10-fold fall in creatinine clearance (0.54 +/- 0.31 ml min-1 kg-1), a 25-fold elevation in urine/plasma glucose concentration ratio (3.28 +/- 0.17), a 20% increase in kidney weight (7.9 +/- 0.56 mg gm-1 body weight) and extensive histological damage 4 days after treatment. In contrast, i.v. carboplatin and p.o. JM216 (the lead compound of this series) caused neither abnormalities in renal function nor histological damage in rats. The nephrotoxicity of single MTD treatments of p.o. ammine/amine Pt(IV) dicarboxylate complexes appears less than i.v. cisplatin and comparable to i.v. carboplatin.

show abstract

Section: Discussionsupporting

confidence: 70%

Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents

McKeage

Morgan²,

Boxall³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Carboplatin is a very attractive drug compared with cisplatin because of its very low nephrotoxicity [44].…”

Section: Discussionmentioning

confidence: 99%

Nephrotoxicity of platinum complexes is related to basolateral organic cation transport

Ludwig¹,

Riethmüller²,

Gekle³

et al. 2004

Kidney International

160

105

View full text Add to dashboard Cite

show abstract

“…Single doses of less than 800 mg m -2 carboplatin have not been found to be nephrotoxic in adults (Skillen et al, 1988;Mason et al, 1991), but renal damage has been documented with higher doses. Adults with ovarian carcinoma treated with single agent carboplatin at a dose of 1000 mg m -3 course -1 (median of 4 courses) had a transient decrease in GFR during treatment which resolved spontaneously after therapy was completed (Hardy et al, 1990).…”

Section: Discussionmentioning

confidence: 99%

Dose-related nephrotoxicity of carboplatin in children

et al. 1999

View full text Add to dashboard Cite

Summary This study investigated changes and the time course of these changes in renal function in children following treatment with carboplatin, and identified risk factors for nephrotoxicity. Glomerular and proximal renal tubular function were investigated before and up to 2 years after treatment in 23 children who received carboplatin. The main findings were reduced glomerular filtration rate (GFR), and increased renal tubular loss of magnesium, manifested by a low serum magnesium (S Mg). The mean fall in GFR was 22 ml min -1 1.73 m -2 (P = 0.012), and in S Mg it was 0.17 mmol l -1 (P = 0.0077). No patient had a clinically important reduction in GFR, and only one patient had symptomatic hypomagnesaemia. GFR and S Mg did not change over time after completion of treatment. Cumulative dose (CD) of carboplatin was inversely related to mean S Mg at the end of treatment (P = 0.031), and directly related to the fall in S Mg (P < 0.001). Calculated cumulative area under the plasma concentration versus time curve (AUC) of carboplatin was inversely related to S Mg after treatment (P = 0.004). Dose intensity (DI) of carboplatin was not shown to be related to S Mg following treatment. CD, AUC and DI of carboplatin were not related to GFR, nor change in GFR, after treatment. High CDs of carboplatin may be associated with evidence of renal damage qualitatively similar to but less severe than that caused by cisplatin. GFR and SMg should be carefully monitored when high CDs of carboplatin are used, or if carboplatin is combined with other nephrotoxic chemotherapy.

show abstract

The effect of carboplatin on renal function in patients with metastatic germ cell tumours

Cited by 13 publications

References 18 publications

Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents

Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents

Nephrotoxicity of platinum complexes is related to basolateral organic cation transport

Dose-related nephrotoxicity of carboplatin in children

Contact Info

Product

Resources

About